<DOC>
	<DOC>NCT00709969</DOC>
	<brief_summary>This study will assess the safety and efficacy of artemether-lumefantrine tablets (6-dose regimen) in African infants / children with acute uncomplicated falciparum malaria.</brief_summary>
	<brief_title>Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets in African Infants and Children With Uncomplicated P. Falciparum Malaria</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria, Falciparum</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<criteria>male or female weighing ≥ 5kg and ≤ 25kg P. falciparum parasitemia between 1,000 and 100,000 parasites/mm3 with confirmed diagnosis of uncomplicated malaria caused P. falciparum parasite complicated malaria ingestion of various antimalarial drugs, or other drugs influencing cardiac function in the previous 4 weeks before study entry to 8 weeks severe anaemia severe malnutrition malaria due to other than P. falciparum Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Malaria</keyword>
	<keyword>co-artemether</keyword>
	<keyword>auditory</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>marsh fever</keyword>
	<keyword>remittent fever</keyword>
	<keyword>artemether</keyword>
	<keyword>artemisinins</keyword>
	<keyword>lumefantrine</keyword>
	<keyword>child</keyword>
	<keyword>infant</keyword>
	<keyword>Africa</keyword>
</DOC>